Table 2.
Prevalence of meningococcal group B vaccine antigen peptide variants in the MRF-MGL for epidemiological years 2010–11 and 2011–12
|
Number of unique peptide sequence variants |
Mean (SD) aminoacid p distance across all variants present |
Most prevalent variant |
Presence of meningococcal group B vaccine peptide variant | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Prevalent (n≥10) | Rare (n<10) | Peptide variant | Number (%) from all isolates (n=899) | Number (%) from genogroup B isolates only (n=668) | Peptide variant | Number (%) from all isolates (n=899) | Number (%) from genogroup B isolates only (n=668) | ||
| fHbp | 12 | 87 | 0·20 (0·13) | 4 | 159 (18%) | 159 (24%) | 1.1 | 34 (4%) | 32 (5%) |
| NadA | 3 | 6 | 0·21 (0·20) | No value* | 797 (89%) | 530 (79%) | 8 | 12 (1%) | 2 (<1%) |
| NHBA | 14 | 70 | 0·13 (0·04) | 2 | 172 (19%) | 172 (26%) | 2 | 172 (19%) | 172 (26%) |
| PorA VR2 | 15 | 40 | 0·62 (0·29) | P1.9 | 137 (15%) | 133 (20%) | P1.4 | 136 (15%) | 136 (20%) |
MRF-MGL=Meningitis Research Foundation Meningococcus Genome Library.
*
Includes genome sequences where the gene was missing, contained a frame-shift mutation, or was incompletely assembled, being interrupted by the end of a contiguous sequence.